NCT03537560View on ClinicalTrials.gov

Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML

CompletedOBSERVATIONAL
Enrollment

334

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Acute Myeloid Leukemia
Trial Locations (1)

33305

Chang Gung Memorial Hospital-Linkou, Taoyuan District

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT03537560 - Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML | Biotech Hunter | Biotech Hunter